Literature DB >> 9865239

Prolonged elimination half-life of phenol after dermal exposure.

Y Bentur1, O Shoshani, A Tabak, A Bin-Nun, Y Ramon, Y Ulman, Y Berger, T Nachlieli, Y J Peled.   

Abstract

BACKGROUND: Phenol is a general protoplastic poison which has been in use in medicine and industry for decades. It is readily absorbed through the skin causing both local and systemic toxicity. CASE REPORT: A 47-year-old male had 90% phenol spilled over his left foot and shoe (3% of body surface area). After a 4 1/2-hour exposure, manifestations included confusion, vertigo, faintness, hypotension, ventricular premature beats, atrial fibrillation, dark-green urine, and tense swelling, blue-black discoloration, hypalgesia, and hypoesthesia of the affected area. Treatment consisted of irrigation with copious amounts of water, incisions, and supportive measures.
RESULTS: Peak serum phenol was 21.6 micrograms/mL, considered in the fatal range. Peak urine phenol plus urine-conjugated phenol was 13,416 mg/g creatinine, indicating a major absorption. Elimination half-life was 13.86 hours, considerably longer than previously reported.
CONCLUSIONS: Prolonged skin contact with concentrated phenol in an occlusive environment may result in a major absorption and a long elimination half-life even if the area involved is small. Prolonged elimination may be explained by extensive tissue distribution or by "slow-release reservoir" properties of the skin. Such exposure may be associated with severe systemic and local toxicities. Immediate removal from exposure and aggressive decontamination of the skin are essential to reduce these risks.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865239     DOI: 10.3109/15563659809162619

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  2 in total

1.  A girl with headache, confusion and green urine.

Authors:  Andreas Hufschmidt; Alexandra Krisch; I Peschen
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

2.  Phenol levels during intralesional curettage and local adjuvant treatment of benign and low-grade malignant bone tumours.

Authors:  Suzan Hm Verdegaal; Jan den Hartigh; Pancras Cw Hogendoorn; Hugo Fg Brouwers; Antonie Hm Taminiau
Journal:  Clin Sarcoma Res       Date:  2012-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.